amyloid beta peptide 25 35 amyloid beta peptide - Amyloid beta25-35 amyloid peptides Understanding Amyloid Beta Peptide 25-35: A Key Player in Neurodegenerative Research

Amyloid beta25-35 The amyloid beta peptide 25-35 (Aβ25-35) is a significant fragment of the larger amyloid-beta protein, a substance that plays a critical role in the pathology of Alzheimer's disease. While the complete amyloid beta protein is implicated in the formation of amyloid plaques in the brain, the Aβ25-35 fragment, specifically, is recognized for its potent neurotoxic effects and is frequently utilized in scientific research to model aspects of neurodegeneration. This article delves into the nature of Aβ25-35, its properties, and its importance in understanding amyloid-related diseases.

The Nature and Properties of Amyloid Beta Peptide 25-35

Amyloid beta peptide 25-35 is a synthetic peptide fragment derived from the human amyloid-beta protein. It is a relatively short sequence, comprising 11 amino acids, which retains key biological characteristics of the full-length amyloid beta proteinbeta-Amyloid (25-35); CAS 131602-53-4. The sequence for this peptide is Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetAlzheimer's Disease β-Amyloid Peptide Is Increased in Mice .... This specific sequence is crucial for its observed biological activities.作者：G Canet·2023·被引用次数：21—The Aβ25–35model appears as a first-intent choice model to rapidly screen the symptomatic or neuroprotective potencies of new compounds. With a molecular weight of approximately 1060.Amyloid β-Protein Fragment35-25≥95% (HPLC); CAS Number: 147740-73-6 at Sigma-Aldrich.3 Da and a molecular formula of C47H82N12O13S, Aβ25-35 is a well-defined molecular entity. It is often supplied with a purity greater than 95%, making it suitable for rigorous scientific investigation.

A key characteristic of amyloid beta peptides, including Aβ25-35, is their propensity to self-assemble into ordered structures, such as oligomers and fibrils. This self-assembly process is believed to be central to their pathological function. The Aβ25-35 peptide fragment, in particular, has been shown to induce apoptosis, a process of programmed cell death作者：L Larini·2012·被引用次数：125—Our simulations show that although the monomer preferentially adopts aβ-hairpin conformation, larger aggregates have extended structures.. This is evidenced by a decrease in cell viability, neuronal DNA condensation, and fragmentation in cellular models.Thispeptidefunctions as a neurotoxic agent in neuronal cell cultures and exhibits pronounced neurotoxicity in various neural cell models. Additionally, it ... This neurotoxic activity makes it a valuable tool for researchers studying the mechanisms of neuronal damage in conditions like Alzheimer's disease作者：N Kandel·2019·被引用次数：65—Theamyloid β(Aβ)peptideand its shorter variants, including a highly cytotoxic Aβ25–35 peptide, exert their neurotoxic effect during ....

Aβ25-35 as a Research Model

The Aβ25-35 fragment is widely employed as a pathomimetic model in Alzheimer's disease researchBeta-Amyloid (25-35). Its ability to rapidly induce cellular and molecular changes associated with neurodegeneration makes it a first-intent choice for screening the symptomatic or neuroprotective potencies of new compounds. Researchers can utilize Aβ25-35 to study various aspects of beta amyloid toxicity, including its interaction with cell membranes. Studies have shown that Aβ25-35 can trigger a reorganization and damage of cell membranes, altering their overall shape and thicknessAmyloid-beta peptide 25-35. This membrane disruption is thought to contribute to the cascade of events leading to neuronal dysfunction and death.

Furthermore, the self-assembly of Aβ25-35 into amyloid oligomers and fibrils is a subject of intense studyBeta-amyloid 25-35induced apoptosis, characterized by decreased cell viability, neuronal DNA condensation, and fragmentation.. While the monomeric form may adopt a β-hairpin conformation, larger aggregates tend to form extended structuresbeta-AmyloidPeptide(25-35) (human), toxicamyloid beta(25-35) protein fragment ... MW 1060.3 Da, Purity >95%. Achieve your results faster with highly validated .... Understanding these conformational changes and the mechanisms of amyloid plaque formation is critical for developing therapeutic strategies. The amyloid hypothesis, which posits that flaws in the processing of the amyloid precursor protein (APP) lead to elevated levels of sticky beta-amyloid forms, is central to much of this research, with Aβ25-35 serving as a key experimental component.

Significance in Alzheimer's Disease Research

Amyloid beta peptides are the primary constituents of amyloid plaques, a hallmark pathological feature found in the brains of individuals with Alzheimer's disease. While the full-length peptides like Aβ(1-40) and Aβ(1-42) are prominent in human AD brains, the Aβ25-35 fragment, though shorter, exhibits pronounced neurotoxic activity. It is considered to be physiologically present in elderly individuals and contributes significantly to the overall neurotoxic effects associated with beta amyloidAmyloid-β (25-35) Peptide (human) (trifluoroacetate salt).

The research into Aβ25-35 extends to understanding how these peptides interact with cellular components and trigger downstream pathological events.Amyloid Beta-peptide (25-35) (human) For instance, studies have explored the role of Aβ25-35 in inducing apoptosis and its functional requirement for both neurotrophic and neurotoxic effects. The development of antibodies targeting specific amyloid beta fragments, including those that recognize Aβ25-35, is also an area of active investigation for potential diagnostic and therapeutic applications.

In summary, amyloid beta peptide 25-35 is a crucial research tool that encapsulates many of the detrimental properties of amyloid beta in a more manageable and potent experimental form. Its use allows scientists to investigate the fundamental mechanisms of neurotoxicity, screen potential drug candidates, and deepen our understanding of amyloid-related neurodegenerative diseases. The study of amyloid and its various fragments, including the significant Aβ25-35, remains at the forefront of efforts to combat conditions like Alzheimer's disease.